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A B S T R A C T
Background: Renal cell carcinoma (RCC) is a highly vascularized cancer resistant to chemotherapy and
radiotherapy. RCC is frequently infiltrated with immune cells, with macrophages being the most
abundant cell type. Alternatively activated M2 macrophages are known to contribute to tumor
progression. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this
study, we investigated the impact of ES gene therapy on the polarization of tumor-associated
macrophages (TAMs) in lung metastases from tumor-bearing mice.
Methods: BALB/c mice divided into three groups: Normal, Control and ES-treated. Tumor-bearing mice
were treated with ES-transduced cells or control cells over ten days. At the end of the study, plasma was
collected, and pulmonary macrophages were isolated and used for FACS or RT-PCR. ELISA tests were used
to analyze plasma and cell culture supernatant cytokines.
Results: ES treatment significantly reduced the levels of anti-inflammatory and pro-angiogenic cytokines,
including IL4, IL-10, IL-13 and VEGF. Gene expression of M2 markers, such as IL-10, Arg-1, VEGF and YM-1,
declined significantly. Flow cytometry showed a reduction in the number of M2 F4/80 + CD36 + CD206 +
CD209+ macrophages and in IL-10 secretion by these cells. Reduced levels of IL-10 were also found in the
culture supernatants of the ES-treated group.
Conclusions: Our research corroborates previous observations that ES has an important anti-tumoral role.
However, aside from promoting interferon-g secretion and an effective Tcell response, we show here that
this switch is extended to TAMs, complicating the maintenance of pro-tumorigenic M2 macrophages and
thus favoring tumor elimination.
ã 2016 Elsevier Masson SAS. All rights reserved.
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Macrophages are among the most important cells of the innate
immune system due to their capacity to effectively stimulate
adaptive immune responses and to promote tissue homeostasis
and repair. In fact, macrophages are widely distributed throughout
the whole body and are known as tissue-resident cells that have
tissue-specific nomenclatures: Kupffer cells reside in the liver,
microglial cells in the central nervous system, Langerhans cells in
the skin, osteoclasts in the bones and many others. It is now
accepted that many of these cells are first derived from the yolk sac,* Corresponding author at: Biotechnology Department, IPEN-CNEN, Sao Paulo,
Brazil.
E-mail address: mhmarumo@terra.com.br (K. Foguer).
http://dx.doi.org/10.1016/j.biopha.2016.01.035
0753-3322/ã 2016 Elsevier Masson SAS. All rights reserved.which may greatly differ from monocyte-derived inflammatory
macrophages that are recruited to inflamed tissues (reviewed in
[1,2]).
In addition to being defined by their tissue specificity,
peritoneal [3] or bone marrow-derived macrophages may also
be characterized by their phenotype, or more precisely, by their
biological activities. In this sense, macrophages may differ greatly
in function, and discrepant populations have been described [2,3].
Indeed, it is currently well accepted that tissue macrophages have
a more suppressive phenotype, whereas inflammatory macro-
phages have stimulatory effects. Although there is no established
consensus regarding these populations (reviewed [4]), the most
widely accepted nomenclature is M1 and M2, or classically and
alternatively activated macrophages, respectively [5,6]. This
nomenclature refers to the activation and functional status of
these cells, and it was first described that M1 are IFN-g and/or LPS-
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phenotype upon stimulation with IL-4, IL-10 or TGF-b [5,6]. Due to
the opposing nature and function of the aforementioned
cytokines, it has also been observed that M1 and
M2 macrophages have opposing transcriptional and phenotypic
profiles [2,3].
M2 macrophages resemble tissue-resident macrophages that
are involved in tissue repair, phagocytosis of cellular debris and
immune suppression and have high expression of arginase-1 [7],
IL-10 [8] and SOCS-3 [6], to note a few examples. [9]
M1 macrophages serve as potent stimulators of the adaptive
immune response and express important pro-inflammatory
molecules and transcription factors, such as iNOS, IL-12 [9], NF-
kB [10] and STAT-1 [11]. Nonetheless, the importance of this
cellular population in several physiological as well as pathological
processes, such as inflammatory and autoimmune diseases [4,12],
pathogenic infections [11] and cancer, has been called into
question (reviewed in [13,14]).
It is very well established that the number of tumor infiltrating
lymphocytes (TILs) directly correlates with tumor growth,
metastasis and patient prognosis [15,16]. Several reports have
demonstrated that the infiltration of CD4 or CD8 IFN-g-secreting
lymphocytes results in increased tumor cell death, as well as
reduced tumor growth and metastasis, resulting in an improved
prognosis and survival rate [15]. This is likely a result of the fact
that several important tumor killing mechanisms are triggered by
IFN-g, such as the secretion of NO [17], TNF-a, and increased
expression of antigen presenting molecules [4,6].
Unfortunately, tumor cells may develop many different
mechanisms to circumvent the immune response, mainly by
triggering suppressive mechanisms. For example, some solid
tumors may recruit T regulatory cells to the tumors, as well as
induce their expansion in draining lymph nodes [18,19].
Interestingly, this is amplified by tolerogenic dendritic cells in
the draining lymph nodes, whose increased expression of
indoleamine-2,3-dioxigenase (IDO) promotes the differentiation
of Tregs [20], rendering the tumors much more refractory to
therapeutic intervention [21,22]. This evidence demonstrates the
importance of the quality of tumor infiltration by immune cells,
i.e., Tregs vs. T effector cells, and also of the interplay between
TILs and innate immunity in tumor elimination and patient
survival.
TAMs have also gained recent attention, as it has been reported
that these cells greatly correlate with tumor progression,
metastasis and overall outcome, similar to T cells (reviewed in
[14,16]). Indeed, similarly to Tregs, tumor-infiltrating macrophages
may actually dampen the immune response in several different
ways. For instance, when T cells were transferred to RAG-deficient
animals, the presence of Th2 lymphocytes secreting IL-4 and IL-
10 greatly reduced the immune effector response, converting TAMs
to an M2 phenotype and rendering the animals more susceptible to
lung metastasis [23]. Moreover, TAMs are able to secrete significant
amounts of the M2 marker CCL2, which in turn may recruit
CD4+CD25+Foxp3+ Tregs to solid ovarian tumors, promoting their
growth and vascularization [24].
Renal cell carcinoma (RCC) is the most common type of kidney
cancer and accounts for approximately 3% of human malignan-
cies. [25] In adults, the most common histologic subtype is clear
cell RCC (ccRCC). Most patients with ccRCC have a mutation in the
tumor suppressor gene von Hippel–Lindau (VHL). The VHL gene
encodes the VHL protein, which is capable of down regulating a
number of intracellular proteins, including hypoxia inducible
factor (HIF). HIF is heterodimeric transcription factor (HIF a/b)
that regulates the expression of genes and facilitates the
adaptation of tissue during hypoxia. In normoxic conditions,
however, VHL protein is involved in the degradation of the HIF asubunit. Loss of function of the VHL gene, even under normal
oxygen pressure, results in an increase in HIF and a consequent
increase in the transcription of several angiogenic factors such as
vascular endothelial growth factor (VEGF), platelet derived
growth factor (PDGF) and basic fibroblast growth factor (FbF)
[26,27]. The presence of these angiogenic factors justifies the
intense vascularization of CCR and contributes substantially to
the development and progression of this disease, explaining the
high prevalence of metastases (30–40%) in the initial diagnosis of
RCC.
Renal cell carcinoma (RCC) is considered to be an immunogenic
tumor and is frequently infiltrated by immune cells. However,
clinicopathological studies have indicated that patients with
higher densities of infiltrating TAMs have significantly poorer
relapse-free survival and overall survival rates. Therefore, TAM
infiltration appears to be a significant unfavorable prognostic
factor in cancer patients and may be a potentially useful prognostic
marker of clinical outcomes.
In this work, we evaluated the functional characteristics of
TAMs in metastatic lungs of mice that underwent antiangiogenic
gene therapy with ES.
2. Material and methods
2.1. Cell Lines
NIH/3T3-LendSN-clone 3 was used for ES expression, and NIH/
3T3-LXSN was used as a control, as described in previous work [10].
Both cell lines were maintained in high-glucose (4.5 g/L at 25 mM)
DMEM medium (Life Technologies Corporation1, Grand Island, NY,
USA) supplemented with 100 U/mL penicillin, 100 mg/mL strepto-
mycin (Gibco1 Life Technologies, NY, EUA), and 10% fetal bovine
serum (FBS) (Life Technologies Corporation1 Grand Island, NY,
USA).
The murine kidney carcinoma cell line (Renca), was maintained
in RPMI 1640 medium (Life Technologies Corporation1 Grand
Island, NY, USA) supplemented with 10% fetal bovine serum (Life
Technologies Corporation1 Grand Island, NY, USA), 2 mM L-
glutamine (Gibco1 Life Technologies, NY, USA), 1 mM sodium
pyruvate (Gibco1 Life Technologies, NY, USA), 1% minimal Eagle’s
medium nonessential amino acids (Gibco1 Life Technologies, NY,
USA), 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco1
Life Technologies, NY, USA).
Both cell lines were maintained at 37 C in a humidified
atmosphere containing 5% CO2.
2.2. Animals
Male BALB/c mice, aged 8–10 weeks, were obtained from the
Animal Facility of IPEN/CNEN-SP, Sao Paulo, Brazil. In these
experiments, 24 mice were used (normal group = 8, control
group = 8, ES-treated group = 8). All animals were cared for in
accordance with the standards of the institute under a protocol
approved by the Animal Experimentation Ethics Committee
(Number of Process: 0260/12).
2.3. Orthotopic metastatic RCC tumor model
Mice were anesthetized by intraperitoneal injection with
ketamine and xylazine (100 mg/kg body weight, Ketalar; Parke-
Davis, Morris Plains, NJ, USA and 10 mg/kg body weight, Phoenix
Scientific, St. Joseph, MO, USA, respectively). The left flank region
was trichotomized and the left kidney was exposed and 2  105
Renca cells suspended in 10 mL of Phosphate Buffered Saline (PBS)
were injected under the renal capsule with the aid of a glass
Table 1
Sequence of Primers used for RT-PCR.
HPRT Forward (F) 50-TGGACAGGACTGAAAGACTT-30
Reverse (R) 50-AATGTAATCCAGCAGGTCAG30
IL-10 Forward (F) 50-CCTCGTGGAGCCTCAGTTTTC-30
Reverse (R) 50-GAGCACGTCAGGTACATTTCAATT-30
IL-12 Forward (F) 50-GCGTGGGAGTGGGATGTG-30
Reverse (R) 50-GCAAAACGATGGCAAACCA-30
Arg-1 Forward (F) 50-AACGGGAGGGTAACCATAAGC-30
Reverse (R) 50-GCGCATTCACAGTCACTTAGGT-30
iNOS Forward (F) 50-GGGCAGCCTGTGAGACCTT-30
Reverse (R) 50-TGAAGCGTTTCGGGATCTG-30
VEGF Forward (F) 50-CCAGACCTCTCACCGGAAAG-30
Reverse (R) 50-CTGTCAACGGTGACGATGATG-30
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the posterior region of the abdomen and was sutured at the region
of the incision.
7 days after Renca cell inoculation, the kidney was removed by
unilateral nephrectomy. Then, mice were divided into two
experimental groups: control group and ES-treated group. These
groups received a subcutaneous injection of 3.6  106 cells NIH/
3T3-LXSN or NIH/3T3-LendSN-clone 3, respectively.
2.4. Obtaining plasma from whole blood
At the end of the experiment, which totaled 17 days, mice were
euthanized in accordance with current standards of the American
Veterinarian Medical Association. Blood samples were collected
into test tubes containing heparin. The plasma components were
separated from whole blood by centrifugation and then stored in a
freezer at 20 C.
2.5. Determination of plasma ES and cytokine levels
Plasma ES levels were measured using a Mouse Endostatin
ELISA Kit (Novateinbio1, Accelerates Research and Development,
USA) according to the manufacturer’s instructions. The ES
concentrations were determined at least in duplicate, and the
assay reproducibility was confirmed. ELISA plates were read using
the Multiskan EX Microplate Reader (Labsystems, Milford, MA,
USA).
The cytokine concentrations were determined using the
Milliplex1 (Mouse Cytokine Magnetic Bead Panel, Millipore),
according to the manufacturer's instructions. The plate was read on
Luminex 200TM device and data were processed using the Xponent
software. We analyzed data from the mean fluorescence intensity
(MFI).
2.6. Isolation of TAMs
The lungs of the mice were perfused with cold saline solution,
and after removal they were maintained in pure DMEM medium.
The lungs were minced with surgical scissors, treated with an
enzyme solution of collagenase D (2.5 mg/mL) (Roche, Mannheim,
Germany) diluted in DMEM and incubated at 37 C for 45 min
with continuous agitation. DMEM with 10% FBS was then added,
and the samples were centrifuged at 450  g for 5 min at 4 C. The
tissue suspension was passed through a 70-mm cell strainer,
subjected to discontinuous Percoll gradient separation (GE
Healthcare1, Uppsala, Sweden) using 37 and 70% dilutions, and
centrifuged at 950  g for 20 min at 4 C with the brakes off. The
cells were collected from the interface between the different
gradients of Percoll and resuspended in the appropriate medium
supplemented with 10% FBS. The cells were centrifuged at 450  g
at 4 C for 5 min and resuspended in 1 mL of the appropriate
culture medium without serum and counted in a Neubauer
chamber.
The isolated cells were seeded in 100-mm cell culture plates in
RPMI-1640 medium for 40 min. Non-adherent cells were removed
by PBS washes, and adhered cells (TAMs) were used for the
following experiments.
2.7. Reverse transcription-polymerase chain reaction (RT-PCR)
RNA was isolated from the adherent cells using the reagent
Qiazol (Qiagen, Germantown, MD, USA). cDNA was synthesized
from 2 mg total RNA with the first-strand cDNA Synthesis kit
(Promega, Heidelberg, Germany), following the manufacturer's
instructions. All RT-PCR reactions were performed using the
ABsolute Mix SYBR Green qPCR kit (Thermo Scientific1 GrandIsland, NY, USA). The 20 mL reactions contained 10 mL of 1 SYBR
Green qPCR Mix, containing the fluorophore SYBR Green I, Taq
polymerase, dNTPs, MgCl2 and buffer the enzyme, and 10 mL
containing primers and H2O. The amplification reaction was
performed by the Real Time Step One Plus PCR System (Applied
Biosystems1) as follows: 50 C for 2 minutes, 95 C for 10 min, and
40 cycles of 95 C for 15 s and 60 C for 1 min. The expression levels
of target genes calculated using the following equation: relative
quantification = 2DDCt. A Ct value was calculated for both the
target gene and the reference gene (HPRT) for each sample. This
value represents the point at which the amplification signal was
detected. From there, the DCt was calculated (Cttargetgene Ct
normalizing[HPRT]). Subsequently, the DDCt was determined
(DCtsample DCtHPRT) using normal (healthy lung) tissue to
compare the level of target gene expression. The DDCt was used
to quantify the relative expression level, where the number 2 is the
sum of the primer efficiencies of the target reference genes, where
both have 100% efficiency. All primers sequences are shown in
Table 1.
2.8. Immunofluorescence
The isolated cells were plated in 24-well plates and after
adhesion were fixed in 4% paraformaldehyde at room temperature
for 10 min. Then, the cells were washed with PBS and incubated
with 1% BSA at 37 C for 1 h to block nonspecific interactions.
Primary antibody to F4/80 (A3-1, MCA497G, AbD Serotec,
Kidlington, UK) was incubated at 4 C overnight. After washes
with PBS, the cells were incubated with anti-IgG secondary
antibody and conjugated with Alexafluor-645 (Invitrogen, Carls-
bad, USA) at room temperature for 1.5 h. Subsequently, the cells
were washed with PBS and kept in mounting media (Prolong Gold
Antifade Reagent, Invitrogen, Carlsbad, USA) containing 40,6-
diamidino-2-phenylindole (DAPI) in the darkroom at 4 C until
acquisition of images.
2.9. Flow cytometry analysis
Cells were seeded at a density of 1 106 per well in a 96-well
plate, and incubated with lipopolysaccharide (LPS) (1 mg/mL)
(Sigma–Aldrich, St. Louis, MO). Cells were incubated with
brefeldin-A (e-Biosciences, San Diego, CA, USA) for 10 h to avoid
cytokine secretion, for subsequent intracellular staining. Cells
surfaces were then stained with anti-F4/80 antibody conjugated to
FITC (BM8, cat. number 11-4801, e-Bioscience, San Diego, CA, USA),
anti-CD11c antibody conjugated to PE (N418, cat. number 12-0114,
e-Bioscience, San Diego, CA, USA), anti-CD206 antibody conjugated
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Serotec, Kidlington, UK), anti-CD80 antibody conjugated to PE (cat.
number 12-0801, e-Bioscience, San Diego, CA, USA), anti-
CD36 antibody conjugated to PE (cat. number 12-0361, e-
Bioscience, San Diego, CA, USA), or anti-CD209 antibody conjugat-
ed to PE (cat. number 122091, e-Bioscience, San Diego, CA, USA)
and fixed with Cytofix/Cytoperm (BD Biosciences, New Jersey,
USA). Cells were then intracellular proteins were stained with anti-
IL-10 antibody conjugated to PE (cat number 554467, BD
Biosciences, New Jersey, USA), anti-IL-12 antibody conjugated to
PE (cat number 554479, BD Biosciences, New Jersey, USA), anti-IL-
12 antibody conjugated to PE-Cy7 (cat number 25-7123, e-
Bioscience, San Diego, CA, USA) and anti-Arginase I antibody
conjugated to PE (cat number IC5868P, BD Biosciences, New Jersey,
USA).
Flow cytometry was performed on a FACS Accuri C6 (BD, San
Diego, CA) with Csampler software for data analysis.
2.10. Culture of macrophages
Following tissue digestion and isolation of macrophages by
density gradient centrifugation, 5 105 macrophages were sepa-
rated and plated in 96-well plates in RPMI. After 2 h to allow cells to
adhere, a wash was performed with PBS, and these cells were
stimulated with 1 mg/mL of LPS in RPMI for 48 h. Cell culture
supernatant was collected and stored at 20 C.
2.11. Determination of cytokine levels in the cell culture supernatant
IL-12 and IL-10 levels were analyzed by capture ELISA using kit
Mouse IL-12 ELISA Set and mouse IL-10 ELISA Set (BD Biosciences,
New Jersey, USA), according to manufacturer's instructions.Fig. 1. Determination of plasma levels of IL-12, IL-10, VEGF, IL-4, IL-13 and TNF-a. Circula
control and ES-treated animals according to the materials and methods. N = 4. One-way A2.12. Statistical analysis
Simple comparisons of means were performed by Student’s T
tests. The multiple mean comparisons were performed using one-
way or two-way ANOVA followed by Bonferroni’s test using the
GraphPad Prism program Version 5.0 Windows (GraphPad1
Software, San Diego, CA, USA), http://www.graphpad.com. Differ-
ences with a p value of p < 0.05 were considered statistically
significant.
3. Results
ES plasma levels of the normal and experimental groups were
measured. The normal group, control group and ES group had
plasma levels of 127.1 9.43 mg/mL, 234.02  6.46 mg/mL and
333.9 mg/mL  9.21, respectively. The presence of tumor cells led
to a 1.84-fold increase in endogenous ES levels in the control group
compared with the normal group (normal vs. control p < 0.001).
The ES group had a 2.62-fold increase in ES plasma levels compared
with the normal group (normal vs. ES p < 0.001) and a 1.42-fold
increase compared with the control group (control vs. ES
p < 0.001). Circulating ES levels corroborated our previous data
[29–36].
3.1. ES treatment decreases anti-inflammatory and pro-angiogenic
cytokines
We began our research by measuring the circulating levels of
cytokines in all three experimental groups using multiplex
cytokine panels. Several cytokines were detected above the lower
limits of detection of the assay in the normal group. Interestingly,
we did not detect differences in Th1-related cytokines, such as IL-
12 and TNF-a in ES-treated animals compared with control
animals (Fig. 1A and F). However, ES treatment significantly
reduced anti-inflammatory and pro-angiogenic cytokines,ting levels of pro or anti-inflammatory cytokines were determined in the plasma of
NOVA followed by Bonferroni by Bonferroni's test. *p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 2. TAM gene expression profile of M1 and M2 markers. TAMs were obtained, enriched and analyzed according to materials and methods and analyzed for the expression
of IL-12, iNOS, IL-10, arginase I, YM-1 and VEGF. (A) Enrichment of TAMs was evaluated by F4/80 (anti-F4/80 Pe) and DAPI (blue) staining. TAMs were visualized at 40
magnification. (B) The gene expression profile was evaluated by qPCR. N = 4. Student’s t-test **p < 0.01; ***p < 0.001. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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expected due to its anti-angiogenic capacity.
3.2. Expression of M2-associated genes were decreased by ES
treatment
We next evaluated the gene expression profile of TAMs.
Accordingly, TAMs were isolated from metastatic lungs and plated
to enrich the macrophages by adherence. The lung weight of the
samples ranged from 0.1 g to 0.5 g and the number of TAMs
collected ranged from 1.0  106 to 2.0  106 cells. F4/80 labeling
confirmed the enrichment of the isolated macrophages of the
lungs (Fig. 2A). RNA was isolated from the macrophages to carry
out gene expression analysis.
The gene expression of the classic M1 markers IL-12, iNOS did
not change significantly in response to ES treatment (Fig. 2B and C).
Interestingly, ES treatment significantly reduced the expression of
several M2 markers, such as IL-10, Arg-1, VEGF and a novel
phenotype marker, YM-1 (Fig. 2D–G).3.3. Macrophage recruitment in metastatic lungs was not altered by ES
treatment
To corroborate previous findings, we next evaluated the
frequency of M1 and M2 macrophages among the TAMs by flow
cytometry. Initially, analysis of the side scatter profile beam (SSC)
and forward scatter profile (FSC) was performed for gating. As
shown in Fig. 3A, TAMs accounted for approximately 51.2% of the
total population (Fig. 3A). This population was then analyzed for
the expression of F4/80 (Fig. 3B). There was a significant increase in
the population of F4/80+ TAMs in the control group compared with
the normal group (17.26  5.98 vs. 12.01 0.46 F4/80+ %, p < 0.05)
(Fig. 3C). No changes were observed among the other groups.
3.4. ES therapy decreases M2 macrophages in the tumor
microenvironment
Next, TAMs were quantified according to M1 and
M2 phenotypes. F4/80+/CD11c+ and F4/80+/CD80+ populations
Fig. 3. Assessment of the frequency of TAMs in the lungs of mice by flow cytometry. (A) Representative gate showing macrophage gating strategy. (B) Representative scatter
charts show the respective percentage of F4/80+ cells, which are quantified, in representative graphs (C). *p < 0.05. N = 4. One-way ANOVA followed by Bonferroni’s test.
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mice (Fig. 4A–D). However, ES treatment caused no change in the
frequency of these populations. Similarly, M2 markers (CD206,
CD209, CD36 and arginase 1) were significantly increased in the
lungs of control group mice. However, ES treatment significantly
decreased the number of M2-polarized macrophages. (Fig. 4E–L).
The production of pro- and anti-inflammatory cytokines was
measured in the macrophages. F4/80/CD11c and F4/80/CD80 cells
were selected (Fig. 4A and C), and IL-12 was identified from them.
The presence of lung metastases resulted in a significant
increase in F4/80+/CD11c+/IL-12+ and F4/80+/CD80+/IL-12+ cells.
However, treatment with ES did not cause a significant change in
any of these populations (Fig. 5A–D). The control group mice had
significantly elevated levels of IL-10-producing macrophages (F4/
80+/CD206+/IL-10+, F4/80+/CD209+/IL-10+ and F4/80+/CD36+/IL-
10+) compared with the normal mice. Treatment with ES promoted
a significant reduction in these populations (Fig. 5E–I).
3.5. Determination of cytokine levels in the cell culture supernatant
The determination of IL-12 and IL-10 in the supernatants of the
macrophage cultures was performed after stimulation with LPS. IL-
12 levels were not significantly different between groups (normal
vs. control, p = 0.45; normal vs. ES, p = 0.07; and control vs. ES,
p = 0.45). However, the amount of IL-10 present in the culture
supernatants was significant increased in the control group
compared with the normal (p < 0.05) and ES (p < 0.01) groups
(Fig. 6).
4. Discussion
In the present work, we sought to evaluate whether treatment
with recombinant ES would modulate the profile of TAMs in ourmodel of lung metastasis. ES is a 20-kDa fragment resulting from
cleavage of the collagen XVIII COOH terminus. This portion has
been described to inhibit endothelial cell proliferation, migration
and invasion, and to dramatically reduce tumor growth and
metastasis in several mouse models with no serious side effects
[28–36]. Of note, using the same model, we have previously
published that ES treatment increased the frequency of pro-
inflammatory TILs, mainly IFN-g-secreting CD4, CD8 and NK cells,
resulting in a reduced number of lung tumor nodules, reduced
metastasis and a higher survival rate [17]. Thus, besides its anti-
angiogenic activity, we have previously demonstrated that ES also
displays an important stimulatory function on T lymphocytes.
Here, our approach was to evaluate whether this effect could be
extended, either directly or indirectly, to TAMs.
Our results clearly demonstrate a contraction of the regulatory
M2 macrophages within the tumoral lung nodules; however, we
observed no change in pro-inflammatory M1 macrophages. We
observed a decrease in several important M2 markers in vivo, such
as arginase-1, Ym-1 and VEGF. Previous research has shown that
reduced intra-tumoral O2 tension induces high expression of HIF-
1a that specifically up-regulates suppressive and pro-angiogenic
molecules, such as PD-1 and VEGF [37]. The importance of VEGF in
tumor growth and establishment of metastases is worth noting.
Accordingly, we observed that ES treatment not only reduced the
expression of VEGFR in macrophages isolated from the metastatic
nodules but also that the ES-treated animals had less soluble VEGF
in plasma than the control group.
Associated with these findings, we also demonstrated through
flow cytometry and intracellular staining that there is not only a
reduction of M2 F4/80+CD36+CD206+CD209+ macrophages but
also a reduction in IL-10 secretion by these populations. The
quantification of the cytokines in culture supernatant also revealed
reduced levels of secreted IL-10 in the ES-treated group. IL-10 is
Fig. 4. Assessment of M1 and M2 macrophage subsets among TAMs by flow cytometry. (A, C, E, G, I, K) Representative scatter charts show the percentage of F4/80+CD11+, F4/
80+CD80+, F4/80+CD206+, F4/80+CD209+, F4/80+ CD36+, and F4/80+Arg1+cells. (B, D, F, H, J, L) Statistical analysis for the data represented in each panel was performed using a
one-way ANOVA followed by a Bonferroni's test. N = 4. *p < 0.05, **p < 0.01, ***p < 0.001.
108 K. Foguer et al. / Biomedicine & Pharmacotherapy 79 (2016) 102–111
Fig. 5. Assessment of IL-10- and IL-12-producing macrophages in the lungs of normal, control and ES-treated mice by flow cytometry. (A and C) Representative scatter charts
show the percentages of F4/80+/CD11c+/IL-12+ and F4/80+/CD80+/IL-12+ cells. (B) (E, G, I) Representative scatter charts show the percentages of F4/80+/CD206+/IL-10+, F4/80+/
CD209+/IL-10+ and F4/80+/CD36+/IL-10+ cells. (B, D, F, H, J) Statistical analysis for the data represented in each panel was performed using one-way ANOVA followed by
Bonferroni’s test. N = 4. *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 6. Determination of IL-12 and IL-10 levels in the macrophage cell culture
supernatant. No significant difference in IL-12 production was found between
groups (normal vs. control, p = 0.45, normal vs. ES, p = 0.07 and control vs. ES,
p = 0.45). A significant increase in the level of secreted IL-10 was observed in the
control group compared with the normal group (*p < 0.05) and ES (**p < 0.01).
Secretion of IL-12 was significantly higher than IL10 in the normal and ES groups
(*p < 0.01 and ***p < 0.001, respectively). N = 4 one-way ANOVA followed by
Bonferroni’s test.
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correlates with immunosuppression and tumor aggressiveness, as
shown in breast tumors [38] and HPV-related cancer [39,40]. These
findings may indicate that the changes observed for TILs described
in our previous research (i.e., the increase in IFN-g-secreting T and
NK cells) may be responsible for these changes observed.
Furthermore, we may not exclude the possibility that ES acts
directly on macrophages or even in a more systemic way, as it has
recently been described as a androgen receptor antagonist [41].
The reduction in IL-10 is coincident with reduction of IL-4, which is
also important in skewing macrophages toward the M2 phenotype.
It is worth mentioning, however, that although these suppressive
cytokines were reduced, no changes were observed for IL-12 and
IL-1b secretion, leading us to speculate that ES may be more
effective in abrogating or dampening M2 expansion, rather than
promoting M1 differentiation.
5. Conclusion
In summary, our research corroborates previous observations
that ES has important anti-tumoral activity. However, aside from
promoting an effective T cell response and interferon-g secretion,
we show here that this switch is extended to TAMs, complicating
the maintenance of pro-tumorigenic M2 macrophages and thus
favoring tumor elimination. Although we refer to tumor infiltrating
immune cells as an “inflammatory infiltrate”, many of these cells in
fact display more of a suppressive phenotype rather than an anti-
tumoral profile. Our findings highlight the conundrum that is the
anti-tumor immune response and the pleiotropic effect of ES in
this model.
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